Field report N-61 / J9 · sheet /deals
M&A & DealsFiled from the territory
Eli Lilly to Buy Blood Cancer Biotech Calytrix for Up to $1.5 Billion
Eli Lilly will pay up to $1.5 billion in cash for Calytrix Bio, a 2025-founded biotech whose preclinical antibody targets rare blood cancers driven by mutant calreticulin.
- Grid
- N-61 / J9
- Surveyed
- November 20, 2026
- Reading
- 2 min read
- Correspondent
- Elena Vasquez

Field notes
- Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion in cash, announced Monday
- Calytrix's lead antibody targets essential thrombocythemia and myelofibrosis driven by mutant calreticulin; it is still preclinical
- Lilly agreed in August to buy Merida Biosciences for up to $2.875 billion
- J.P. Morgan Life Sciences Private Capital founded Calytrix in 2025
- Lilly's hematology business already markets the FDA-cleared blood cancer drug Jaypirca
Eli Lilly agreed on Monday to acquire Calytrix Bio, a privately held developer of therapies for rare blood cancers, for up to $1.5 billion in cash.
The deal is the Indianapolis drugmaker's latest move to broaden its oncology and hematology pipeline beyond its core diabetes and weight-loss franchise. Lilly agreed in August to buy Merida Biosciences for up to $2.875 billion, adding a developer of therapies that target disease-causing antibodies.
What does the acquisition include?
Under the definitive agreement, Calytrix shareholders could receive up to $1.5 billion. That total combines an upfront payment with further payments tied to clinical and regulatory milestones, the company said. Neither party disclosed the size of the upfront payment, and Calytrix gave no expected closing date, according to Reuters.
Calytrix's lead asset is an investigational antibody for essential thrombocythemia (ET) and myelofibrosis (MF), two myeloproliferative neoplasms driven by mutant calreticulin. The antibody is still preclinical. It targets both Type 1 and Type 2 mutant calreticulin, the company said.
Why does the target matter?
Current drug therapies for ET and MF primarily manage symptoms and complications rather than addressing the underlying disease biology, according to the company. The acquisition therefore gives Lilly a potential disease-modifying candidate in a field with limited treatment options.
"Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, Calytrix's president and chief executive officer, in a statement. Prosek said the company looks forward to Lilly advancing the program through the clinic.
The purchase also broadens Lilly's presence in myeloproliferative neoplasms. The company's hematology business already sells Jaypirca, a blood cancer drug cleared by the U.S. Food and Drug Administration, according to Reuters.
Who is behind Calytrix?
Calytrix is young even by biotech standards. J.P. Morgan Life Sciences Private Capital founded the company in 2025. Its financing history spans two rounds:
- A Series A co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners
- A Series B led by Avoro Ventures
That means Lilly is buying a startup launched in the same year as the deal itself, before its lead molecule has reached human trials.
Who advised on the deal?
Centerview Partners serves as exclusive financial adviser to Calytrix, with Goodwin Procter as its legal counsel. Paul, Weiss, Rifkind, Wharton & Garrison is legal counsel to Lilly.
The acquisition continues a run of Lilly transactions as the company seeks to reduce its reliance on diabetes and weight-loss products, according to Reuters.
via qz.com (Source)
More from Elena Vasquez
Show full bio
Staff writer covering companies, deals and strategy in corporate strategy and chief-executive leadership at CEO Frontier.
514 articles
Adjacent sheets
- Lilly's $25B Push Anchors 50-Plus Biopharma M&A Deals in H1
- Eli Lilly breaks ground on $3.5 billion Lehigh Valley facility
- SELLAS Vaccine Cuts Death Risk 41% as Patent Expiry Starts in 2026
- Blackstone to Fund Up to $1.5 Billion of Pfizer Weight-Loss Drug
- Ellipses Pharma targets £450m-£500m London listing in February